





MRN: \_\_\_\_\_  
DOB: \_\_\_\_\_

**Phone: 1-800-809-1265 Fax: 1-866-872-8920**

**Guidelines for Prescribing VIMIZIM® (elosulfase alfa)**  
(Required documentation with all initial referrals)

**Patient Name:** \_\_\_\_\_ **Referral Date:** \_\_\_\_\_

\_\_\_\_\_ Include signed and completed **Plan of Treatment**. (MD must complete sections 1-87)  
(Infusion order forms & Standard Adverse Reactions orders are available at [www.palmettoinfusion.com](http://www.palmettoinfusion.com) under Agency/MD tab)

\_\_\_\_\_ Include patient demographic information and insurance information. (Copy of insurance cards if available)

\_\_\_\_\_ **Supporting clinical MD notes to include any past tried and/or failed therapies, intolerance, outcomes or contraindications to conventional therapy. Please include clinical documentation to support diagnosis.**

- Vimizim® is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome).

\_\_\_\_\_ Other as requested: \_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

**\*\* Warnings/Precautions: Anaphylaxis and Hypersensitivity Reactions:** Life-threatening anaphylaxis and hypersensitivity reactions have been observed in some patients during treatment with Vimizim. If anaphylaxis or severe hypersensitivity reactions occur, immediately stop the infusion and initiate appropriate medical treatment. Pre-treatment with antihistamines with or without antipyretics is recommended prior to the start of infusion. **Risk of Acute Respiratory Complications:** Patients with acute febrile or respiratory illness may be at higher risk of life-threatening complications from hypersensitivity reactions. Careful consideration should be given to the patient's clinical status prior to administration of Vimizim and consider delaying the Vimizim infusion. The most common adverse reactions (≥10% in Vimizim patients and occurring at a higher incidence than placebo-treated patients) were pyrexia, vomiting, headache, nausea, abdominal pain, chills, and fatigue. **Pregnancy/Breastfeeding:** Discuss Pregnancy or breastfeeding plans/risks prior to start of therapy. See full prescribing information

**Palmetto Infusion Services will complete insurance verification and submit all required clinical documentation to the patient's insurance company for eligibility. Our office will notify you if any further information is required. We will review financial responsibility with the patient and refer them to any available Co-pay assistance as required. Thank you for the referral.**

**Please fax all information to 1-866-872-8920 or call 1-800-809-1265 for assistance.**